ATE227134T1 - Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen - Google Patents

Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen

Info

Publication number
ATE227134T1
ATE227134T1 AT96941743T AT96941743T ATE227134T1 AT E227134 T1 ATE227134 T1 AT E227134T1 AT 96941743 T AT96941743 T AT 96941743T AT 96941743 T AT96941743 T AT 96941743T AT E227134 T1 ATE227134 T1 AT E227134T1
Authority
AT
Austria
Prior art keywords
chitosan
intranasal administration
vaccine compositions
compositions
antigens
Prior art date
Application number
AT96941743T
Other languages
English (en)
Inventor
Lisbeth Illum
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Application granted granted Critical
Publication of ATE227134T1 publication Critical patent/ATE227134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96941743T 1995-12-07 1996-12-09 Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen ATE227134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9525083.3A GB9525083D0 (en) 1995-12-07 1995-12-07 Vaccine compositions
PCT/GB1996/003019 WO1997020576A1 (en) 1995-12-07 1996-12-09 Vaccine compositions for intranasal administration comprising chitosan and use thereof

Publications (1)

Publication Number Publication Date
ATE227134T1 true ATE227134T1 (de) 2002-11-15

Family

ID=10785093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941743T ATE227134T1 (de) 1995-12-07 1996-12-09 Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen

Country Status (13)

Country Link
US (2) US6391318B1 (de)
EP (1) EP0865297B1 (de)
JP (1) JP4063876B2 (de)
AT (1) ATE227134T1 (de)
CA (1) CA2237529C (de)
DE (1) DE69624726T2 (de)
DK (1) DK0865297T3 (de)
ES (1) ES2186809T3 (de)
GB (2) GB9525083D0 (de)
NO (1) NO323084B1 (de)
NZ (1) NZ323973A (de)
PT (1) PT865297E (de)
WO (1) WO1997020576A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
ATE403436T1 (de) * 1999-03-24 2008-08-15 Secr Defence Polykationische karbohydrate als immunostimulierende mittel in impstoffen
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
AU2001276831A1 (en) 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
ES2295391T3 (es) 2001-08-16 2008-04-16 Cmp Therapeutics Limited Microparticulas de quitina y sus usos medicos.
CN100333792C (zh) 2001-09-28 2007-08-29 南佛罗里达大学 Rsv基因表达疫苗
WO2003043574A2 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
MXPA04011248A (es) * 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
JP4675317B2 (ja) * 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
WO2004074314A2 (en) 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US8796235B2 (en) * 2003-02-21 2014-08-05 University Of South Florida Methods for attenuating dengue virus infection
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
JP2006525354A (ja) * 2003-05-01 2006-11-09 アルキメデス・ディヴェロップメント・リミテッド Ｌｈ−ｒｈアナログロイプロイドの経鼻投与
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US7740883B2 (en) * 2004-03-28 2010-06-22 University Of Debrecen Nanoparticles from chitosan
EP1742612A2 (de) * 2004-05-06 2007-01-17 Ivrea Pharmaceuticals, Inc. Partikel zur wirkstofffreisetzung
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
JPWO2006030730A1 (ja) * 2004-09-15 2008-05-15 大塚製薬株式会社 経粘膜用組成物、及び経粘膜吸収の向上方法
WO2007086923A2 (en) * 2005-05-23 2007-08-02 University Of South Florida Controlled and sustained gene transfer mediated by thiol-modified polymers
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US8536324B2 (en) * 2005-10-21 2013-09-17 University Of South Florida Method of drug delivery by carbon nanotube-chitosan nanocomplexes
CA2628313A1 (en) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
PT1965787E (pt) 2005-11-30 2013-07-05 Endo Pharmaceuticals Inc Tratamento de xerostomia com um antioxidante que contém enxofre
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP2009541281A (ja) 2006-06-20 2009-11-26 シーエムピー セラピューティクス リミテッド キチンマイクロ粒子を含む組成物およびそれらの医学的使用
HUE032422T2 (en) * 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
EP2112923A1 (de) 2007-01-22 2009-11-04 Targacept Inc. Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
EP2167069B1 (de) 2007-05-23 2011-10-26 Amcol International Corporation Mit cholesterin interagierende phyllosilikate und verfahren zur reduktion von hypercholesterinämie bei einem säuger
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US8741313B2 (en) * 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
AU2009219204B2 (en) 2008-02-27 2013-01-17 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010119112A1 (en) * 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
CA2871786C (en) 2012-04-24 2021-11-16 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
US10279028B2 (en) 2012-04-24 2019-05-07 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
CN108715607B (zh) * 2018-04-12 2021-12-10 华南农业大学 重组霍乱毒素b亚基蛋白、pedv灭活疫苗及制备与应用
CN109172817B (zh) * 2018-08-16 2021-10-26 华中农业大学 猪流行性腹泻病毒减毒活疫苗壳聚糖微球的制备方法及其应用
EP3698773A1 (de) 2019-02-21 2020-08-26 Università degli Studi di Parma Zusammensetzung und herstellung von pulvern mit nanoadjuvanzien zur mukosalen impfung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US4950740A (en) * 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
AU688603B2 (en) 1994-09-23 1998-03-12 Zonagen, Inc. Chitosan induced immunopotentiation
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
EP0857059A1 (de) * 1995-06-26 1998-08-12 Research Triangle Pharmaceuticals Ltd. Neuartige adjuvanszusammensetzung und sie enthaltende impfstoffformulierung
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions

Also Published As

Publication number Publication date
DK0865297T3 (da) 2003-03-03
WO1997020576A1 (en) 1997-06-12
NO982497D0 (no) 1998-06-02
US6391318B1 (en) 2002-05-21
DE69624726D1 (de) 2002-12-12
GB2322801B (en) 2000-01-19
AU705452B2 (en) 1999-05-20
AU1102597A (en) 1997-06-27
ES2186809T3 (es) 2003-05-16
JP4063876B2 (ja) 2008-03-19
EP0865297A1 (de) 1998-09-23
NO323084B1 (no) 2006-12-27
US20030039665A1 (en) 2003-02-27
GB9811810D0 (en) 1998-07-29
DE69624726T2 (de) 2003-09-18
EP0865297B1 (de) 2002-11-06
GB9525083D0 (en) 1996-02-07
GB2322801A (en) 1998-09-09
JP2000501412A (ja) 2000-02-08
NO982497L (no) 1998-06-02
NZ323973A (en) 2004-12-24
PT865297E (pt) 2003-03-31
CA2237529C (en) 2008-10-14
CA2237529A1 (en) 1997-06-12
US7323183B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
ATE227134T1 (de) Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen
DE122010000040I1 (de) Solubilisierung von capsulären Polysacchariden
NL300331I1 (nl) Kweken van lawsonia intracellularis, vaccins tegenlawsonia
NO981963L (no) Influensavaksine-blandinger
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
ES2196110T3 (es) Composiciones de silicona reticulables, un procedimiento de preparacion y su uso..
AU4161296A (en) Influenza vaccine
WO1998040097A3 (en) Bovine respiratory and enteric coronavirus as a vaccine
ATE193974T1 (de) Chlamydia impfstoffen
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
HU9801705D0 (en) Streptococcus equi vaccine
BR9914004A (pt) Composições imunogênicas de lipossomas
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
UA67258A (en) Strain neonatal calf diarrhea coronavirus "bc-1" for the preparation of vaccines and diagnosticums

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0865297

Country of ref document: EP

EEFA Change of the company name